Table 1.
Subject ID | Age | Sex | Blood CD4+ | CDC Stage | ADC Stage | HIV-1 RNA | Antiretroviral therapies | |
baseline (nadir) | CSF | Plasma | ||||||
(years) | (cells/μL) | (log10 copies/ml) | ||||||
San Francisco | ||||||||
6004 | 56 | M | 275 (116) | B3 | 0 | <1.29 | 4,11 | d4T,3TC,IDV |
6008 | 39 | M | 834 (360) | A2 | 0 | 1,61 | <1.29 | SQV, RTV |
6011 | 47 | M | 375 (191) | B3 | 0,5 | <1.29 | 1,41 | ZDV, 3TC, EFV |
6012 | 54 | M | 464 (199) | B3 | 0 | <1.29 | 1,57 | d4T, 3TC, EFV |
6013 | 44 | M | 618 (275) | C2 | 0 | <1.29 | 3,69 | d4T, 3TC, EFV |
Göteborg | ||||||||
160 | 51 | M | 544 (195) | C3 | 0 | <1.29 | <1.29 | ZDV, 3TC, IDV |
207 | 47 | M | 428 (210) | A2 | 0 | <1.29 | <1.29 | ZDV, 3TC, SQV, NFV |
223 | 56 | F | 365 (110) | B3 | 0 | <1.29 | <1.29 | ZDV, 3TC, IDV/RTV |